Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Altimmune management will host a conference call and webcast with a slide presentation beginning at
Conference Call Information:
Date: | |
Time: | |
(844) 615-6509 | |
International Dial-in: | (918) 922-3148 |
Conference ID: | 3792068 |
Webcast: | https://edge.media-server.com/mmc/p/ojyxaxpp |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor and Media Contact:
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
Source: Altimmune, Inc